The financing will help fund continued development of its healthcare data platform that integrates electronic medical record (EHR), individual genomic profile, and personal health device data.
Already a leader among U.S. health systems in using genomics to guide care, the strategic alliance between NorthShore and Sema4 will significantly expand NorthShore’s existing clinical genomics offerings to more than 1,000 physicians and approximately 300,000 NorthShore patients.
The NIH-funded ROSALIND Diagnostic Monitoring platform has just been launched to provide test developers and regulators with rapid and regular updates about SARS-CoV-2 variants of concern and their distribution and assess the impact of these variants on available diagnostic test performance.
This new data was obtained using a combination of advanced sequencing and mapping technologies. Importantly, each of the genomes was assembled without guidance from the first human genome composite. As a result, the new dataset captures genetic differences from different human populations.
The partnership, whose value was not disclosed, will leverage the real-world clinic-genomic database developed by Flatiron and Foundation Medicine, called CGDB, for both the potential identification of new therapeutic targets as well as help inform the design of future clinical trials.
Upon closing of the transaction, expected in the second quarter, CM Life Sciences will be renamed and its stock listed on Nasdaq global exchange. The deal values Sema4 at $2 billion.
When the pandemic heated up early last year, the UK Biobank set out to urgently gather data on COVID-19 diagnostic tests, deaths, and hospitals...
The researchers showed that men of African ancestry inherit about twice the prostate cancer risk on average compared to men of European ancestry. In contrast, men of Asian ancestry inherit about three-quarters the risk of their white counterparts.
The companies say that through AI-enhanced interrogation of medical literature and phenotypes associated with rare disease, researchers will be better able to make new and unexpected discoveries based on rare disease data.
The OneOncology Research Network (OneR), a subsidiary of OneOncology, will provide operational, regulatory, and research support services with the aim of more efficiently executing multi-center clinical trials.